Congress moves to make birth control available without a prescription

What it does

This bill directs the FDA to fast-track approval of over-the-counter oral contraceptive drugs for adults 18 and older, waives FDA application fees for such drugs, and requires a Government Accountability Office study of federal spending on contraception over the past 15 years across Medicare, Medicaid, military health, and other programs. Minors remain subject to existing prescription requirements.

Why we flagged it

The bill's core mechanism is regulatory streamlining—fast-track FDA review and fee waiver—designed to move oral contraceptives from prescription to over-the-counter status for adults. The GAO study is a secondary transparency measure.

What the text implies

• Fee waiver reduces FDA revenue from drug application fees; magnitude depends on number of supplemental applications filed but is likely modest.
• Priority review may accelerate approval timelines, potentially reducing FDA's ability to conduct thorough safety review if resources are not adjusted.
• OTC status removes prescriber gatekeeping; women gain autonomy but lose opportunity for clinical counseling on drug interactions, contraindications, or side effects.
• GAO study scope (15-year retrospective) may reveal significant federal spending on contraception, potentially informing future budget debates or policy changes.
• Minors remain prescription-only; creates a two-tier access system that may complicate pharmacy operations and raise questions about age-verification enforcement.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Women aged 18+ gain direct pharmacy access to oral contraceptives without prescription barriers, reducing delays and out-of-pocket costs associated with doctor visits. The GAO study increases transparency on federal contraception spending, supporting informed policy debate. Minors retain existing protections.

Who stands to gain

• oral contraceptive manufacturers (faster approval, fee waiver)
• pharmacies (new OTC sales channel)
• women aged 18+ (reduced out-of-pocket costs from eliminated doctor visits)

Named in the bill

FDA (Food and Drug Administration), HHS (Department of Health and Human Services), GAO (Government Accountability Office), Medicare, Medicaid, Indian Health Service, Federally-qualified health centers, TRICARE, Title X of the Public Health Service Act

Where it stands

3 cosponsors: 3 Republicans.

• Mar 25, 2026 — Introduced · Congress.gov: “Introduced in House”
• Mar 25, 2026 — Referred to House Committee on Armed Services and House Committee on Natural Resources · Congress.gov: “Referred to the Committee on Energy and Commerce, and in addition to the Committees on Ways and Means…”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

1 lobbying clients named this bill on 1 disclosure filings across 1 quarter, Jun 2026 to Jun 2026. Those filings disclosed $420,000 in lobbying spend. A filing names 51 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 0% of bills with at least one filing.

Ashley Hinson, the sponsor, reported $963,000 in PAC receipts in the 2026 cycle.

• Susan B Anthony List — $420,000 on 1 filing

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.